Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Thalassemia - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 29 Aug 17

The "Thalassemia - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Thalassemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 8, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Thalassemia - Overview
  3. Thalassemia - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Thalassemia - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Thalassemia - Companies Involved in Therapeutics Development
  • Acceleron Pharma Inc
  • Agios Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • bluebird bio Inc
  • Cadila Healthcare Ltd
  • Calimmune Inc
  • CRISPR Therapeutics
  • Editas Medicine Inc
  • Errant Gene Therapeutics LLC
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • Incyte Corp
  • Ionis Pharmaceuticals Inc
  • IRBM Science Park SpA
  • Kiadis Pharma NV
  • La Jolla Pharmaceutical Company
  • Merck & Co Inc
  • Protagonist Therapeutics Inc
  • Sangamo Therapeutics Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 29/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.